Mackenzie Financial Corp Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Mackenzie Financial Corp bought a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 41,485 shares of the company's stock, valued at approximately $2,483,000.

A number of other large investors have also bought and sold shares of the business. Treasurer of the State of North Carolina lifted its stake in Apellis Pharmaceuticals by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 43,800 shares of the company's stock valued at $1,666,000 after acquiring an additional 230 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in shares of Apellis Pharmaceuticals by 69.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company's stock worth $25,000 after buying an additional 265 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Apellis Pharmaceuticals by 2.4% in the 3rd quarter. Arizona State Retirement System now owns 23,211 shares of the company's stock valued at $883,000 after acquiring an additional 541 shares in the last quarter. Covestor Ltd increased its position in shares of Apellis Pharmaceuticals by 564.2% in the third quarter. Covestor Ltd now owns 797 shares of the company's stock valued at $30,000 after acquiring an additional 677 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company's stock worth $115,000 after acquiring an additional 687 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. The Goldman Sachs Group increased their price target on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a "buy" rating in a research note on Tuesday, January 9th. Raymond James upped their price objective on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a "strong-buy" rating in a research report on Thursday, January 11th. JPMorgan Chase & Co. upped their price target on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an "overweight" rating in a research report on Wednesday, March 6th. Wedbush decreased their price objective on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a "neutral" rating for the company in a research report on Wednesday, April 17th. Finally, Jefferies Financial Group raised shares of Apellis Pharmaceuticals from a "hold" rating to a "buy" rating and lifted their price target for the company from $68.00 to $80.00 in a research note on Monday, February 5th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $77.93.

Insider Buying and Selling

In other news, insider Nur Nicholson sold 835 shares of the firm's stock in a transaction on Monday, January 29th. The shares were sold at an average price of $64.14, for a total value of $53,556.90. Following the sale, the insider now directly owns 67,507 shares in the company, valued at approximately $4,329,898.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 250,000 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $64.11, for a total value of $16,027,500.00. Following the sale, the chief executive officer now owns 313,662 shares of the company's stock, valued at $20,108,870.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Nur Nicholson sold 835 shares of the company's stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $64.14, for a total transaction of $53,556.90. Following the transaction, the insider now directly owns 67,507 shares of the company's stock, valued at approximately $4,329,898.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 381,011 shares of company stock valued at $23,463,657. Company insiders own 7.50% of the company's stock.

Apellis Pharmaceuticals Stock Up 2.3 %

Shares of APLS traded up $1.08 during mid-day trading on Tuesday, hitting $48.72. The company's stock had a trading volume of 1,184,393 shares, compared to its average volume of 1,486,838. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $5.87 billion, a price-to-earnings ratio of -10.87 and a beta of 0.88. Apellis Pharmaceuticals, Inc. has a 52-week low of $19.83 and a 52-week high of $94.75. The company's 50-day moving average is $59.31 and its 200-day moving average is $57.36.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. During the same quarter last year, the business posted ($1.50) EPS. The company's revenue was up 545.9% on a year-over-year basis. On average, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.33 EPS for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).